Neuland Laboratories

Neuland Laboratories ROA

The Return on Assets (ROA) of Neuland Laboratories (NEULANDLAB.NS) as of Oct 29, 2026 is 12.42 %. In the previous year, Return on Assets (ROA) was 11.93 % — a change of 4.11% (higher).

ROA

12.42 %

YoY

4.11%

Last updated:

In 2026, Neuland Laboratories's return on assets (ROA) was 12.42 %, a 4.11% increase from the 11.93 % ROA in the previous year.

The Neuland Laboratories ROA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROA
Date
ROA
Jan 1, 2019
1.45 INR
Jan 1, 2020
1.32 INR
Jan 1, 2021
6.09 INR
Jan 1, 2022
4.61 INR
Jan 1, 2023
10.35 INR
Jan 1, 2024
16.37 INR
Jan 1, 2025
11.93 INR
Jan 1, 2026
12.42 INR
The Neuland Laboratories ROA history
YEARROAYoY
12.42 %+4.11%
11.93 %-27.13%
16.37 %+58.20%
10.35 %+124.38%
4.61 %-24.20%
6.09 %+362.18%
1.32 %-9.47%
1.45 %+29.19%
1.13 %-78.72%
5.29 %+1.49%
5.21 %+67.25%
3.12 %-43.77%
5.54 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Neuland Laboratories Stock analysis

What does Neuland Laboratories do? Neuland Laboratories Ltd. generates revenue through the manufacture and export of bulk pharmaceutical ingredients and intermediates for the generics industry. The company operates in a single segment focused on active pharmaceutical ingredients (APIs) and allied services, with two business verticals: generic drug substances (GDS) and custom manufacturing solutions (CMS). Its products include Levetiracetam, Mirtazapine, Ciprofloxacin, Enalapril, Sotalol, and Labetalol, which are supplied to both domestic and international markets. The firm provides end-to-end chemistry solutions for the pharmaceutical industry, covering synthesis of library compounds, NCEs, and advanced intermediates across clinical and commercial stages. The company's primary customers are pharmaceutical firms requiring APIs and intermediates for generic drugs, with a focus on global markets. Neuland Laboratories Ltd. serves as a solution provider for chemistry needs, offering services from early-stage development to commercial production. The business model emphasizes tailored manufacturing services under CMS, alongside standardized GDS products, catering to the full lifecycle of pharmaceutical development and production. Revenue streams are derived from the sale of specific APIs like Levetiracetam and Mirtazapine, as well as custom manufacturing services for complex chemical processes. The firm's dual verticals allow it to address diverse market demands, with GDS targeting cost-effective generic drug production and CMS focusing on specialized, high-value manufacturing solutions for pharmaceutical clients. Neuland Laboratories is one of the most popular companies on Eulerpool.

ROA Details

Understanding Neuland Laboratories's Return on Assets (ROA)

Neuland Laboratories's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.

Year-to-Year Comparison

Comparing Neuland Laboratories's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.

Impact on Investments

Investors consider Neuland Laboratories's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.

Interpreting ROA Fluctuations

Variations in Neuland Laboratories’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.

Frequently Asked Questions about Neuland Laboratories stock

Return on Assets (ROA) of Neuland Laboratories is 12.42 % in 2026.

Return on Assets (ROA) of Neuland Laboratories changed from 11.93 % to 12.42 %, representing a 4.11% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Return on Assets (ROA) Neuland Laboratories since 2006 – with annual values, charts, and detailed analysis.

Return on Assets, also known as ROA, is a financial metric used to measure a company's profitability. It is used to determine how effectively a company uses its assets to generate profits. It is also referred to as the ratio of net income to total assets. ROA is an important indicator of a company's overall financial performance as it measures the company's ability to generate more profit from the assets it employs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Assets (ROA)'s Neuland Laboratories with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Assets (ROA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Assets (ROA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Profitability — Neuland Laboratories

ROEROAROCEROICAsset TurnoverInventory TurnoverReceivables TurnoverDays Sales OutstandingDays Inventory OutstandingDays Payable OutstandingCash Conversion CycleCROICGross Profit/AssetsFixed Asset TurnoverEquity TurnoverWorking Capital TurnoverPayables TurnoverCapital IntensityReceivables/RevenueInventory/RevenueEBIT/Assets

All Key Metrics — Neuland Laboratories